Reduced uptake of oxidized low density lipoproteins in monocyte-derived macrophages from CD36-deficient subjects. 1995

S Nozaki, and H Kashiwagi, and S Yamashita, and T Nakagawa, and B Kostner, and Y Tomiyama, and A Nakata, and M Ishigami, and J Miyagawa, and K Kameda-Takemura
Second Department of Internal Medicine, Osaka University Medical School, Japan.

To clarify the physiological roles of CD36 as an oxidized low density lipoprotein (OxLDL) receptor, we analyzed the monocyte-derived macrophages from normal and two CD36-deficient subjects, since we identified the molecular abnormalities (Kashiwagi, H., Y. Tomiyama, Y. Kosugi, M. Shiraga, R. H. Lipsky, Y. Kanayama, Y. Kurata, and Y. Matsuzawa 1994. Blood. 83:3545-3552; and Kashiwagi, H., Y. Tomiyama, S. Honda, S. Kosugi, M. Shiraga, N. Nagao, S. Sekiguchi, Y. Kanayama, Y. Kurata, and Y. Matsuzawa. 1995. J. Clin. Invest. 95:1040-1046). Scatchard analysis of 125I-OxLDL binding showed a linear plot and the maximum binding was lower by approximately 40% in the macrophages from subjects with CD36 deficiency than those from normal controls. Competition studies showed that the uptake of 125I-OxLDL was suppressed by OKM5, an antibody against CD36, by 53% in normal control macrophages, but not in the CD36-deficient macrophages. After incubation with OxLDL for 24 h, cholesteryl ester mass accumulation was reduced by approximately 40% in the macrophages from CD36-deficient subjects than those from normal controls. These results suggest that CD36 is one of the physiological receptors for OxLDL. Since specific binding of OxLDL was only reduced by approximately 40% in spite of the complete deficiency of CD36, several other receptors also may have some role in OxLDL uptake. Further studies will be needed to assess the quantitative role of CD36 in foam cell formation in vivo.

UI MeSH Term Description Entries
D008077 Lipoproteins, LDL A class of lipoproteins of small size (18-25 nm) and light (1.019-1.063 g/ml) particles with a core composed mainly of CHOLESTEROL ESTERS and smaller amounts of TRIGLYCERIDES. The surface monolayer consists mostly of PHOSPHOLIPIDS, a single copy of APOLIPOPROTEIN B-100, and free cholesterol molecules. The main LDL function is to transport cholesterol and cholesterol esters to extrahepatic tissues. Low-Density Lipoprotein,Low-Density Lipoproteins,beta-Lipoprotein,beta-Lipoproteins,LDL(1),LDL(2),LDL-1,LDL-2,LDL1,LDL2,Low-Density Lipoprotein 1,Low-Density Lipoprotein 2,LDL Lipoproteins,Lipoprotein, Low-Density,Lipoproteins, Low-Density,Low Density Lipoprotein,Low Density Lipoprotein 1,Low Density Lipoprotein 2,Low Density Lipoproteins,beta Lipoprotein,beta Lipoproteins
D008264 Macrophages The relatively long-lived phagocytic cell of mammalian tissues that are derived from blood MONOCYTES. Main types are PERITONEAL MACROPHAGES; ALVEOLAR MACROPHAGES; HISTIOCYTES; KUPFFER CELLS of the liver; and OSTEOCLASTS. They may further differentiate within chronic inflammatory lesions to EPITHELIOID CELLS or may fuse to form FOREIGN BODY GIANT CELLS or LANGHANS GIANT CELLS. (from The Dictionary of Cell Biology, Lackie and Dow, 3rd ed.) Bone Marrow-Derived Macrophages,Monocyte-Derived Macrophages,Macrophage,Macrophages, Monocyte-Derived,Bone Marrow Derived Macrophages,Bone Marrow-Derived Macrophage,Macrophage, Bone Marrow-Derived,Macrophage, Monocyte-Derived,Macrophages, Bone Marrow-Derived,Macrophages, Monocyte Derived,Monocyte Derived Macrophages,Monocyte-Derived Macrophage
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009000 Monocytes Large, phagocytic mononuclear leukocytes produced in the vertebrate BONE MARROW and released into the BLOOD; contain a large, oval or somewhat indented nucleus surrounded by voluminous cytoplasm and numerous organelles. Monocyte
D010084 Oxidation-Reduction A chemical reaction in which an electron is transferred from one molecule to another. The electron-donating molecule is the reducing agent or reductant; the electron-accepting molecule is the oxidizing agent or oxidant. Reducing and oxidizing agents function as conjugate reductant-oxidant pairs or redox pairs (Lehninger, Principles of Biochemistry, 1982, p471). Redox,Oxidation Reduction
D002478 Cells, Cultured Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others. Cultured Cells,Cell, Cultured,Cultured Cell
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D018955 CD36 Antigens Leukocyte differentiation antigens and major platelet membrane glycoproteins present on MONOCYTES; ENDOTHELIAL CELLS; PLATELETS; and mammary EPITHELIAL CELLS. They play major roles in CELL ADHESION; SIGNAL TRANSDUCTION; and regulation of angiogenesis. CD36 is a receptor for THROMBOSPONDINS and can act as a scavenger receptor that recognizes and transports oxidized LIPOPROTEINS and FATTY ACIDS. Antigens, CD36,OKM5 Antigen,Platelet Glycoprotein IV,Platelet Membrane Glycoprotein IIIb,Receptors, Thrombospondin,Scavenger Receptors, Class B, Type I,Thrombospondin Receptors,Adipocyte Membrane Protein p88,CD36 Antigen,CD36 Antigen (Collagen Type I Receptor, Thrombospondin Receptor),CD36 Fatty Acid Transporter,CD36 Protein,FAT (Fatty Acid Translocase) - CD36 Antigen,GPIIIb Platelet Glycoprotein,GPIV Platelet Glycoprotein,Platelet Glycoprotein IIIb,Platelet Membrane Glycoprotein IV,SR-BI Protein,SR-BI Receptor,Thrombospondin Receptor,Antigen, CD36,Antigen, OKM5,Glycoprotein IIIb, Platelet,Glycoprotein IV, Platelet,Platelet Glycoprotein, GPIIIb,Platelet Glycoprotein, GPIV,Receptor, SR-BI,Receptor, Thrombospondin,SR BI Protein,SR BI Receptor

Related Publications

S Nozaki, and H Kashiwagi, and S Yamashita, and T Nakagawa, and B Kostner, and Y Tomiyama, and A Nakata, and M Ishigami, and J Miyagawa, and K Kameda-Takemura
October 2000, European journal of biochemistry,
S Nozaki, and H Kashiwagi, and S Yamashita, and T Nakagawa, and B Kostner, and Y Tomiyama, and A Nakata, and M Ishigami, and J Miyagawa, and K Kameda-Takemura
January 2018, Arteriosclerosis, thrombosis, and vascular biology,
S Nozaki, and H Kashiwagi, and S Yamashita, and T Nakagawa, and B Kostner, and Y Tomiyama, and A Nakata, and M Ishigami, and J Miyagawa, and K Kameda-Takemura
September 1996, Zhongguo yao li xue bao = Acta pharmacologica Sinica,
S Nozaki, and H Kashiwagi, and S Yamashita, and T Nakagawa, and B Kostner, and Y Tomiyama, and A Nakata, and M Ishigami, and J Miyagawa, and K Kameda-Takemura
May 1982, The Biochemical journal,
S Nozaki, and H Kashiwagi, and S Yamashita, and T Nakagawa, and B Kostner, and Y Tomiyama, and A Nakata, and M Ishigami, and J Miyagawa, and K Kameda-Takemura
December 1998, The Journal of experimental medicine,
S Nozaki, and H Kashiwagi, and S Yamashita, and T Nakagawa, and B Kostner, and Y Tomiyama, and A Nakata, and M Ishigami, and J Miyagawa, and K Kameda-Takemura
August 1990, The Journal of biological chemistry,
S Nozaki, and H Kashiwagi, and S Yamashita, and T Nakagawa, and B Kostner, and Y Tomiyama, and A Nakata, and M Ishigami, and J Miyagawa, and K Kameda-Takemura
January 1989, Arteriosclerosis (Dallas, Tex.),
S Nozaki, and H Kashiwagi, and S Yamashita, and T Nakagawa, and B Kostner, and Y Tomiyama, and A Nakata, and M Ishigami, and J Miyagawa, and K Kameda-Takemura
March 1989, Biochemical and biophysical research communications,
S Nozaki, and H Kashiwagi, and S Yamashita, and T Nakagawa, and B Kostner, and Y Tomiyama, and A Nakata, and M Ishigami, and J Miyagawa, and K Kameda-Takemura
May 1988, The Journal of clinical investigation,
S Nozaki, and H Kashiwagi, and S Yamashita, and T Nakagawa, and B Kostner, and Y Tomiyama, and A Nakata, and M Ishigami, and J Miyagawa, and K Kameda-Takemura
June 1991, Biochimica et biophysica acta,
Copied contents to your clipboard!